BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation
Budding uninhibited by benzimidazoles 1 (BUB1) is a mitotic checkpoint serine/threonine kinase that has been reported as an oncogene or tumor suppressor gene in various types of cancer, including breast cancer, pancreatic ductal adenocarcinoma, prostate and gastric cancers. However, its role in live...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2020-05, Vol.19 (5), p.3506-3512 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3512 |
|---|---|
| container_issue | 5 |
| container_start_page | 3506 |
| container_title | Oncology letters |
| container_volume | 19 |
| creator | Zhu, Li-Jing Pan, Yan Chen, Xiao-Ying Hou, Pan-Fei |
| description | Budding uninhibited by benzimidazoles 1 (BUB1) is a mitotic checkpoint serine/threonine kinase that has been reported as an oncogene or tumor suppressor gene in various types of cancer, including breast cancer, pancreatic ductal adenocarcinoma, prostate and gastric cancers. However, its role in liver cancer remains unclear. The present study aimed to explore the biological function of BUB1 in liver cancer. The present study demonstrated that BUB1 mRNA expression levels and the intensity of immunohistochemical staining were significantly increased in liver cancer tissues compared with normal tissues. The role of BUB1 in cell proliferation was also determined. Overexpression of BUB1 significantly promoted cell proliferation, whereas knockdown of BUB1 expression inhibited the proliferation of liver cancer cell lines. In experiments investigating the underlying mechanism, overexpression of BUB1 increased the levels of SMAD2 phosphorylation, whereas knockdown of BUB1 reduced the levels of SMAD2 phosphorylation. Therefore, BUB1 may promote proliferation of liver cancer cells by activating phosphorylation of SMAD2, and BUB1 may serve as a potential target in the diagnosis and/or treatment of liver cancer. |
| doi_str_mv | 10.3892/ol.2020.11445 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7114935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2387588593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-19530c3d399434c4a0441913a45dbea0260e4aca9a81b6fe2c5a6a9c0f34a4ad3</originalsourceid><addsrcrecordid>eNpdkc1LAzEQxYMoKrVHr7LgxcvWfG6Ti-C3QsWD9hxms1ldSTc12Rb635u1taiBYQbyy2NeHkLHBI-YVPTcuxHFFI8I4VzsoEMyVjQnWNLd7TzmB2gY4wdORxREymIfHTBKC1VQfoimV9Mrks2Dn_nOxn5wTW0DdI1vM19nrlnakBloTd-sczErVxmYrlkmpn3LXp4ub2g2f_cxVVi575dHaK8GF-1w0wdoenf7ev2QT57vH68vJ7nhRHQ5UYJhwyqmFGfccMCcE0UYcFGVFjAtsOVgQIEkZVFbagQUoAyuGQcOFRugi7XufFHObGVs2wVweh6aGYSV9tDovzdt867f_FKP048pJpLA2UYg-M-FjZ2eNbG3Ca31i6gpkxJjVqQaoNN_6IdfhDbZ66mxkFIolqh8TZngYwy23i5DsO4z097pPjP9nVniT3472NI_CbEvcGqSGQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2387588593</pqid></control><display><type>article</type><title>BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Zhu, Li-Jing ; Pan, Yan ; Chen, Xiao-Ying ; Hou, Pan-Fei</creator><creatorcontrib>Zhu, Li-Jing ; Pan, Yan ; Chen, Xiao-Ying ; Hou, Pan-Fei</creatorcontrib><description>Budding uninhibited by benzimidazoles 1 (BUB1) is a mitotic checkpoint serine/threonine kinase that has been reported as an oncogene or tumor suppressor gene in various types of cancer, including breast cancer, pancreatic ductal adenocarcinoma, prostate and gastric cancers. However, its role in liver cancer remains unclear. The present study aimed to explore the biological function of BUB1 in liver cancer. The present study demonstrated that BUB1 mRNA expression levels and the intensity of immunohistochemical staining were significantly increased in liver cancer tissues compared with normal tissues. The role of BUB1 in cell proliferation was also determined. Overexpression of BUB1 significantly promoted cell proliferation, whereas knockdown of BUB1 expression inhibited the proliferation of liver cancer cell lines. In experiments investigating the underlying mechanism, overexpression of BUB1 increased the levels of SMAD2 phosphorylation, whereas knockdown of BUB1 reduced the levels of SMAD2 phosphorylation. Therefore, BUB1 may promote proliferation of liver cancer cells by activating phosphorylation of SMAD2, and BUB1 may serve as a potential target in the diagnosis and/or treatment of liver cancer.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2020.11445</identifier><identifier>PMID: 32269624</identifier><language>eng</language><publisher>Greece: Spandidos Publications UK Ltd</publisher><subject>Biotechnology ; Breast cancer ; Cancer therapies ; Kinases ; Laboratories ; Liver cancer ; Medical prognosis ; Mortality ; Oncology ; Plasmids ; Proteins ; Radiation therapy ; Surgery</subject><ispartof>Oncology letters, 2020-05, Vol.19 (5), p.3506-3512</ispartof><rights>Copyright: © Zhu et al.</rights><rights>Copyright Spandidos Publications UK Ltd. 2020</rights><rights>Copyright: © Zhu et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-19530c3d399434c4a0441913a45dbea0260e4aca9a81b6fe2c5a6a9c0f34a4ad3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114935/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114935/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32269624$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Li-Jing</creatorcontrib><creatorcontrib>Pan, Yan</creatorcontrib><creatorcontrib>Chen, Xiao-Ying</creatorcontrib><creatorcontrib>Hou, Pan-Fei</creatorcontrib><title>BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Budding uninhibited by benzimidazoles 1 (BUB1) is a mitotic checkpoint serine/threonine kinase that has been reported as an oncogene or tumor suppressor gene in various types of cancer, including breast cancer, pancreatic ductal adenocarcinoma, prostate and gastric cancers. However, its role in liver cancer remains unclear. The present study aimed to explore the biological function of BUB1 in liver cancer. The present study demonstrated that BUB1 mRNA expression levels and the intensity of immunohistochemical staining were significantly increased in liver cancer tissues compared with normal tissues. The role of BUB1 in cell proliferation was also determined. Overexpression of BUB1 significantly promoted cell proliferation, whereas knockdown of BUB1 expression inhibited the proliferation of liver cancer cell lines. In experiments investigating the underlying mechanism, overexpression of BUB1 increased the levels of SMAD2 phosphorylation, whereas knockdown of BUB1 reduced the levels of SMAD2 phosphorylation. Therefore, BUB1 may promote proliferation of liver cancer cells by activating phosphorylation of SMAD2, and BUB1 may serve as a potential target in the diagnosis and/or treatment of liver cancer.</description><subject>Biotechnology</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Plasmids</subject><subject>Proteins</subject><subject>Radiation therapy</subject><subject>Surgery</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkc1LAzEQxYMoKrVHr7LgxcvWfG6Ti-C3QsWD9hxms1ldSTc12Rb635u1taiBYQbyy2NeHkLHBI-YVPTcuxHFFI8I4VzsoEMyVjQnWNLd7TzmB2gY4wdORxREymIfHTBKC1VQfoimV9Mrks2Dn_nOxn5wTW0DdI1vM19nrlnakBloTd-sczErVxmYrlkmpn3LXp4ub2g2f_cxVVi575dHaK8GF-1w0wdoenf7ev2QT57vH68vJ7nhRHQ5UYJhwyqmFGfccMCcE0UYcFGVFjAtsOVgQIEkZVFbagQUoAyuGQcOFRugi7XufFHObGVs2wVweh6aGYSV9tDovzdt867f_FKP048pJpLA2UYg-M-FjZ2eNbG3Ca31i6gpkxJjVqQaoNN_6IdfhDbZ66mxkFIolqh8TZngYwy23i5DsO4z097pPjP9nVniT3472NI_CbEvcGqSGQ</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Zhu, Li-Jing</creator><creator>Pan, Yan</creator><creator>Chen, Xiao-Ying</creator><creator>Hou, Pan-Fei</creator><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200501</creationdate><title>BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation</title><author>Zhu, Li-Jing ; Pan, Yan ; Chen, Xiao-Ying ; Hou, Pan-Fei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-19530c3d399434c4a0441913a45dbea0260e4aca9a81b6fe2c5a6a9c0f34a4ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biotechnology</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Plasmids</topic><topic>Proteins</topic><topic>Radiation therapy</topic><topic>Surgery</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Li-Jing</creatorcontrib><creatorcontrib>Pan, Yan</creatorcontrib><creatorcontrib>Chen, Xiao-Ying</creatorcontrib><creatorcontrib>Hou, Pan-Fei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Li-Jing</au><au>Pan, Yan</au><au>Chen, Xiao-Ying</au><au>Hou, Pan-Fei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>19</volume><issue>5</issue><spage>3506</spage><epage>3512</epage><pages>3506-3512</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Budding uninhibited by benzimidazoles 1 (BUB1) is a mitotic checkpoint serine/threonine kinase that has been reported as an oncogene or tumor suppressor gene in various types of cancer, including breast cancer, pancreatic ductal adenocarcinoma, prostate and gastric cancers. However, its role in liver cancer remains unclear. The present study aimed to explore the biological function of BUB1 in liver cancer. The present study demonstrated that BUB1 mRNA expression levels and the intensity of immunohistochemical staining were significantly increased in liver cancer tissues compared with normal tissues. The role of BUB1 in cell proliferation was also determined. Overexpression of BUB1 significantly promoted cell proliferation, whereas knockdown of BUB1 expression inhibited the proliferation of liver cancer cell lines. In experiments investigating the underlying mechanism, overexpression of BUB1 increased the levels of SMAD2 phosphorylation, whereas knockdown of BUB1 reduced the levels of SMAD2 phosphorylation. Therefore, BUB1 may promote proliferation of liver cancer cells by activating phosphorylation of SMAD2, and BUB1 may serve as a potential target in the diagnosis and/or treatment of liver cancer.</abstract><cop>Greece</cop><pub>Spandidos Publications UK Ltd</pub><pmid>32269624</pmid><doi>10.3892/ol.2020.11445</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2020-05, Vol.19 (5), p.3506-3512 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7114935 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Biotechnology Breast cancer Cancer therapies Kinases Laboratories Liver cancer Medical prognosis Mortality Oncology Plasmids Proteins Radiation therapy Surgery |
| title | BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A02%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BUB1%20promotes%20proliferation%20of%20liver%20cancer%20cells%20by%20activating%20SMAD2%20phosphorylation&rft.jtitle=Oncology%20letters&rft.au=Zhu,%20Li-Jing&rft.date=2020-05-01&rft.volume=19&rft.issue=5&rft.spage=3506&rft.epage=3512&rft.pages=3506-3512&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2020.11445&rft_dat=%3Cproquest_pubme%3E2387588593%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2387588593&rft_id=info:pmid/32269624&rfr_iscdi=true |